Search results
Showing 211 to 225 of 1259 results for pathway
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
Evidence-based recommendations on AposHealth for knee osteoarthritis.
accuracy of objective tests that could be used to comprisea diagnostic pathway for asthma in children and young people aged 5 to 16 (for...
Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.
This quality standard covers preventing and controlling infections in hospitals and other secondary care settings that develop because of treatment or from being in a healthcare setting (healthcare-associated infections). It includes monitoring, responsibilities, and policies and procedures in secondary care organisations to reduce the risk of infection in patients, staff and visitors. It describes high-quality care in priority areas for improvement.
View quality statements for QS113Show all sections
Sections for QS113
- Quality statements
- Quality statement 1: Surveillance
- Quality statement 2: Collaborative action
- Quality statement 3: Responsibilities of hospital staff
- Quality statement 4: Planning, design and management of hospital facilities
- Quality statement 5: Admission, discharge and transfer
- About this quality standard
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.
The PLASMA system for transurethral resection and haemostasis of the prostate (HTG563)
Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate.